DE69841573D1 - Verfahren zur erhöhung der magnesiumabsorption und verhinderung von artheriosklerose - Google Patents

Verfahren zur erhöhung der magnesiumabsorption und verhinderung von artheriosklerose

Info

Publication number
DE69841573D1
DE69841573D1 DE69841573T DE69841573T DE69841573D1 DE 69841573 D1 DE69841573 D1 DE 69841573D1 DE 69841573 T DE69841573 T DE 69841573T DE 69841573 T DE69841573 T DE 69841573T DE 69841573 D1 DE69841573 D1 DE 69841573D1
Authority
DE
Germany
Prior art keywords
magnesium absorption
increasing magnesium
magnesium
artherosclerosis
preventing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69841573T
Other languages
English (en)
Inventor
Michael W Dixon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE69841573D1 publication Critical patent/DE69841573D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Botany (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69841573T 1997-06-27 1998-06-25 Verfahren zur erhöhung der magnesiumabsorption und verhinderung von artheriosklerose Expired - Lifetime DE69841573D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/883,287 US5849337A (en) 1997-06-27 1997-06-27 Method of enhancing magnesium absorption and prevention of atherosclerosis
PCT/US1998/013098 WO1999000015A1 (en) 1997-06-27 1998-06-25 Method of enhancing magnesium absorption and prevention of atherosclerosis

Publications (1)

Publication Number Publication Date
DE69841573D1 true DE69841573D1 (de) 2010-05-06

Family

ID=25382325

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69841573T Expired - Lifetime DE69841573D1 (de) 1997-06-27 1998-06-25 Verfahren zur erhöhung der magnesiumabsorption und verhinderung von artheriosklerose

Country Status (8)

Country Link
US (1) US5849337A (de)
EP (1) EP1003370B1 (de)
JP (1) JP3622985B2 (de)
AT (1) ATE461705T1 (de)
AU (1) AU7986798A (de)
CA (1) CA2295108C (de)
DE (1) DE69841573D1 (de)
WO (1) WO1999000015A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372264B1 (en) * 2000-08-24 2002-04-16 Gusty Winds Corporation Method of reducing calcified arterial plaque buildup and cellular malfunction and for balancing ionic calcium
US8017160B2 (en) 2003-08-15 2011-09-13 Russell Jaffe Enhancement of magnesium uptake in mammals
AU2004269872A1 (en) * 2003-09-05 2005-03-17 Matthias Rath Pharmaceutical composition comprising I.A. vitamin C, magnesium, green tea extract for retarding cardiovascular diseases
US7799937B2 (en) 2004-10-25 2010-09-21 Synthonics, Inc. Metal coordinated compositions
US20060141054A1 (en) * 2004-10-25 2006-06-29 Thomas Piccariello Metal coordinated compositions
US8779175B2 (en) * 2004-10-25 2014-07-15 Synthonics, Inc. Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients
GB0606212D0 (en) * 2006-03-28 2006-05-10 Karobio Ab Pharmaceutical compositions
KR101483207B1 (ko) * 2014-06-25 2015-01-22 한국지질자원연구원 고흡수성 마그네슘 복합체의 제조방법
US11357250B2 (en) 2016-08-15 2022-06-14 Summit Innovation Labs LLC Treatment and prevention of diabetes and obesity
US11344575B2 (en) 2016-08-15 2022-05-31 Summit Innovation Labs, LLC Vascular calcification prevention and treatment
EP4236699A1 (de) 2020-10-28 2023-09-06 Balchem Corporation Verfahren zur erhöhung der bioverfügbarkeit und absorption von magnesium

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4167562A (en) * 1978-08-28 1979-09-11 Evers H Ray Method and composition for treating arteriosclerosis
US4497800A (en) * 1982-07-06 1985-02-05 Mead Johnson & Company Stable liquid diet composition
US4725427A (en) * 1984-03-13 1988-02-16 Albion International, Inc. Effervescent vitamin-mineral granule preparation
US5162344A (en) * 1987-05-04 1992-11-10 Robert Koch Procaine double salt complexes
DE3938992A1 (de) * 1989-11-21 1991-05-23 Schering Ag Kaskadenpolymer-gebundene komplexbildner, deren komplexe und konjugate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
US5278189A (en) * 1990-06-04 1994-01-11 Rath Matthias W Prevention and treatment of occlusive cardiovascular disease with ascorbate and substances that inhibit the binding of lipoprotein (A)
US5292538A (en) * 1992-07-22 1994-03-08 Metagenics, Inc. Improved sustained energy and anabolic composition and method of making
US5549905A (en) * 1994-10-18 1996-08-27 Clintec Nutrition Co. Enternal composition for pediatric patients
GB2306109B (en) * 1997-02-07 1997-09-24 John Wright A zinc containing composition as a common cold prophylactic

Also Published As

Publication number Publication date
CA2295108A1 (en) 1999-01-07
US5849337A (en) 1998-12-15
CA2295108C (en) 2004-06-01
EP1003370B1 (de) 2010-03-24
ATE461705T1 (de) 2010-04-15
JP3622985B2 (ja) 2005-02-23
EP1003370A4 (de) 2004-04-21
AU7986798A (en) 1999-01-19
EP1003370A1 (de) 2000-05-31
JP2001506277A (ja) 2001-05-15
WO1999000015A1 (en) 1999-01-07

Similar Documents

Publication Publication Date Title
GT199800126A (es) Terapia de combinacion.
AP9801392A0 (en) Concentrated antibody preparation.
NZ503233A (en) Synergistic analgesic combination of opioid analgesic and COX-2 inhibitor
ES2172944T3 (es) Forma de dosificacion osmotica que comprende un primer y un segundo revestimiento.
WO1994027589A3 (en) Antidepressant dosage form
NL300258I2 (nl) Farmaceutische samenstelling voor toepassing in debehandeling van.
BR9807577A (pt) Método para prevenir e retardar o inìcio da doença de alzheimer e sua composição
IL124536A (en) Pharmaceutical compositions containing a glycine uptake antagonist
ES2191174T3 (es) (-)hidroxicitrato de magnesio, procedimiento de preparacion, aplicaciones y composiciones principalmente farmaceuticas que lo contienen.
DE69434121D1 (de) Pharmazeutische zusammensetzung zur immunstimulierenden therapie
PT996460E (pt) Tratamento da fibrose renal com anticorpos contra integrina alfa-v-beta 6
DE69841573D1 (de) Verfahren zur erhöhung der magnesiumabsorption und verhinderung von artheriosklerose
DE60128912D1 (en) Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika
DE69719754D1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
UA32457C2 (uk) Лікарський засіб (варіанти) і спосіб медикаментозного впливу на організм
AU5170499A (en) Use of ginkgo biloba extracts for preparing a medicine for treating amyotrophic lateral sclerosis
PL340679A1 (en) Application of a mixture of diole and alpha-hydroxyacid in treating
NZ326345A (en) Composition containing diosgenin
HK1032534A1 (en) L-threonate ferrous, as well as pharmaceutical composition and use for improving and treating human anemia thereof
MY108692A (en) Topical composition
PT862454E (pt) Novas utilizacoes de ctla-8 de mamifero e reagentes relacionados
IL126161A0 (en) Method for treating autism
PL328924A1 (en) Method of treating abuse of substances
BR9801839A (pt) Medicamento analgésico e aplicação de (+) -0-demetiltramadol.
TR200000728T2 (tr) Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition